{"id":"NCT02513550","sponsor":"Eli Lilly and Company","briefTitle":"A Study Comparing Different Dosing Regimens of Ixekizumab (LY2439821) in Participants With Moderate to Severe Plaque Psoriasis","officialTitle":"A Multicenter, Randomized, Double-Blind Study Comparing the Efficacy and Safety of Ixekizumab Dosing Regimens in Patients With Moderate-to-Severe Plaque Psoriasis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-08","primaryCompletion":"2016-11","completion":"2017-08-03","firstPosted":"2015-07-31","resultsPosted":"2018-04-18","lastUpdate":"2020-06-17"},"enrollment":1257,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Plaque Psoriasis"],"interventions":[{"type":"DRUG","name":"Ixekizumab","otherNames":["LY2439821"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"80 mg Ixekizumab Q2W","type":"EXPERIMENTAL"},{"label":"80 mg Ixekizumab Q4W","type":"EXPERIMENTAL"},{"label":"80 mg Ixekizumab Q4W/Q2W","type":"EXPERIMENTAL"},{"label":"80 mg Ixekizumab Q2W Maximum Extended Enrollment (ME2) Cohort","type":"EXPERIMENTAL"},{"label":"80 mg Ixekizumab Q4W Maximum Extended Enrollment Cohort","type":"EXPERIMENTAL"},{"label":"80 mg Ixekizumab Q4W/Q2W Maximum Extended Enrollment Cohort","type":"EXPERIMENTAL"}],"summary":"The main purpose of this study is to evaluate the efficacy of ixekizumab dosing regimens in participants with plaque psoriasis.","primaryOutcome":{"measure":"Percentage of Participants Achieving Static Physician Global Assessment (sPGA) of (0,1)","timeFrame":"Week 52","effectByArm":[{"arm":"80 mg Ixekizumab Q4W","deltaMin":70.6,"sd":null},{"arm":"80 mg Ixekizumab Q4W/Q2W","deltaMin":72.5,"sd":null},{"arm":"80 mg Ixekizumab Q2W","deltaMin":78.6,"sd":null}],"pValues":[{"comp":"OG000 vs OG002","p":"=0.005"},{"comp":"OG000 vs OG001","p":"=0.522"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":11},"locations":{"siteCount":125,"countries":["United States","Argentina","Australia","Canada","Czechia","Germany","Hungary","Japan","Mexico","Poland","Puerto Rico","Romania","South Korea","Taiwan"]},"refs":{"pmids":[],"seeAlso":["http://www.lillytrialguide.com/EN-us/studies/psoriasis/rhbp"]},"adverseEventsSummary":{"seriousAny":{"events":16,"n":310},"commonTop":["Viral upper respiratory tract infection","Upper respiratory tract infection","Injection site reaction","Headache","Arthralgia"]}}